News & Videos - BIOM UP SA - English

DGAP-News: Biom'up / Key word(s): Regulatory Approval Biom'up announces the approval of HEMOBLAST(TM) Bellows and its laparoscopic applicator in Australia 07.10.2019 / 08:00 The issuer is solely responsible for the content of this announcement. Biom'up announces the approval of HEMOBLAST TM Bellows and its laparoscopic applicator in Australia Successful review of HEMOBLAST Bellows' performance and safety profile as well as Biom'up's Quality Management System by the Australian Therapeutic Goods...

DGAP-News: Biom'up / Key word(s): Half Year Results Biom'up: Approval of 2019 H1 interim results postponed: Board of Directors pursues review of options available to the Company 30.09.2019 / 19:00 The issuer is solely responsible for the content of this announcement. Approval of 2019 H1 interim results postponed: Board of Directors pursues review of options available to the Company Estimated total sales of HEMOBLAST(TM) Bellows for the first nine months of 2019 are expected to show strong growth...

DGAP-News: Biom'up / Key word(s): Personnel Biom'up strengthens management team 18.09.2019 / 08:00 The issuer is solely responsible for the content of this announcement. Biom'up strengthens management team Veteran MedTech executive Patrice Ferrand is appointed CEO Experienced pharmaceutical and biotech industry executive Evelyne Nguyen is appointed Group CFO Dr. Jan Ohrstrom continues his tenure as Chairman of the Board Current CCO for the United States George Makhoul is appointed CEO of Biom'up...

DGAP-News: Biom'up / Key word(s): Study Biom'up: New Publication Highlights Application of HEMOBLAST(TM) Bellows in Cardiovascular Surgery 14.08.2019 / 08:00 The issuer is solely responsible for the content of this announcement. New Publication Highlights Application of HEMOBLAST TM Bellows in Cardiovascular Surgery Article describes successful use and advantages of HEMOBLAST Bellows in high risk patients prone to bleeding undergoing cardiovascular surgical procedures. Saint-Priest, France,...

DGAP-News: Biom'up / Key word(s): Financing Biom'up issues a new tranche of EUR 5 million from the credit line granted by Athyrium 07.08.2019 / 18:00 The issuer is solely responsible for the content of this announcement. Biom'up issues a new tranche of EUR 5 million from the credit line granted by Athyrium Issue of bonds with warrants attached, fully subscribed by Athyrium within the framework of the EUR 35 million facility announced on April 3, 2018 A cash shortfall now estimated as of early...

DGAP-News: Biom'up / Key word(s): Half Year Results Biom'up Provides Business Update for the First Half of 2019 and confirms its Revenue Guidance for the year 10.07.2019 / 08:00 The issuer is solely responsible for the content of this announcement. Biom'up Provides Business Update for the First Half of 2019 and confirms its Revenue Guidance for the year Global, unaudited sales of HEMOBLAST(TM) Bellows for the first half of 2019 were EUR1.4 million - on track to achieve 2019 revenue guidance...

DGAP-News: Biom'up / Key word(s): Personnel Industry Veteran Dr. Jan Ohrstrom takes on Executive Leadership of Biom'up 31.05.2019 / 08:00 The issuer is solely responsible for the content of this announcement. Industry Veteran Dr. Jan Ohrstrom takes on Executive Leadership of Biom'up Saint-Priest, France, May 31, 2019 - 8h00 (CET) - Biom'up SA (the "Company "), specializing in surgical hemostasis, today announced a change in the Company's leadership position. Etienne Binant steps down from his...

DGAP-News: Biom'up / Key word(s): Conference Biom'up to Present at the RBC Capital Markets Global Healthcare Conference on Tuesday May 21, 2019 in New York City 20.05.2019 / 20:00 The issuer is solely responsible for the content of this announcement. Biom'up to Present at the RBC Capital Markets Global Healthcare Conference on Tuesday May 21, 2019 in New York City Saint-Priest, France, May 20, 2019 - 18h00 (CET) - Biom'up (the « Company »), specializing in surgical hemostasis, today announced...

DGAP-News: Biom'up / Key word(s): Forecast Biom'up provides 2019 guidance for HEMOBLAST(TM) Bellows global sales 20.05.2019 / 08:00 The issuer is solely responsible for the content of this announcement. Biom'up provides 2019 guidance for HEMOBLAST TM Bellows global sales Biom'up provides full-year 2019 guidance for global sales of HEMOBLAST Bellows in the range of EUR4.0-4.5 million 2019 operational expenditures forecasted to decrease significantly versus 2018 Operational break-even on a...

DGAP-News: Biom'up / Key word(s): Annual Results Biom'up reports 2018 full-year results and provides a business update 30.04.2019 / 08:00 The issuer is solely responsible for the content of this announcement. Biom'up reports 2018 full-year results and confirms strong commercial uptake in 1 st quarter of 2019 Saint-Priest, France, April 30, 2019, 8:00 am (CET) - Biom'up (the " Company "), a specialist in surgical hemostasis, today announced its full-year results for the year ending December 31,...

DGAP-News: Biom'up / Key word(s): Study Biom'up granted FDA IDE approval for HEMOSNOW(TM) 24.04.2019 / 08:00 The issuer is solely responsible for the content of this announcement. Biom'up granted FDA IDE approval for HEMOSNOW TM Saint-Priest, France, April 24, 2019 - 8h00 (CET) - Biom'up (the « Company »), specializing in surgical hemostasis, announced today that the U.S. Food and Drug Administration (FDA) approved the IDE (Investigational Device Exemption) application for HEMOSNOW, a...

DGAP-News: Biom'up / Key word(s): Agreement Biom'up announces first US sales in laparoscopy for HEMOBLAST(TM) Bellows and the signing of an exclusive distribution agreement for HEMOBLAST(TM) Bellows in Australia 15.04.2019 / 08:00 The issuer is solely responsible for the content of this announcement. Biom'up announces first US sales in laparoscopy for HEMOBLAST TM Bellows and the signing of an exclusive distribution agreement for HEMOBLAST TM Bellows in Australia Successful launch of the...

DGAP-News: Biom'up / Key word(s): Miscellaneous Biom'up Notice of 2018 Year End results 12.04.2019 / 08:00 The issuer is solely responsible for the content of this announcement. Biom'up Notice of 2018 Year End Results Saint-Priest, France, April 12th, 2019 - 8h00 (CEST) - Biom'up SA (the « Company »), specializing in surgical hemostasis, will announce its results for the full year, ending December 31st, 2018 on April 30th, 2019 before European markets open. Biom'up will disclose FY 2018...

DGAP-News: Biom'up / Key word(s): Personnel Biom'up appoints George Makhoul as Chief Commercial Officer (USA) 31.01.2019 / 08:00 The issuer is solely responsible for the content of this announcement. Biom'up appoints George Makhoul as Chief Commercial Officer (USA) Saint-Priest, France, January 31, 2019 - 8h00 (CET) - Biom'up (the « Company »), specializing in surgical hemostasis, today announced the appointment of George Makhoul as Chief Commercial Officer with responsibility for the United...

DGAP-News: Biom'up / Key word(s): Scientific publication Biom'up HEMOBLAST(TM) Bellows full pivotal trial results published in Journal of Cardiac Surgery 30.01.2019 / 08:00 The issuer is solely responsible for the content of this announcement. Biom'up HEMOBLAST TM Bellows full pivotal trial results published in Journal of Cardiac Surgery Article provides full data set of pivotal clinical trial showing that HEMOBLAST Bellows is clinically and statistically superior to control at achieving...

DGAP-News: Biom'up / Key word(s): Regulatory Approval Biom'up granted FDA approval for its HEMOBLAST(TM) Bellows Laparoscopic Applicator 22.01.2019 / 08:00 The issuer is solely responsible for the content of this announcement. Biom'up granted FDA approval for its HEMOBLAST TM Bellows Laparoscopic Applicator HEMOBLAST Bellows can be used with a specially designed 35 cm cannula in the United States in minimally-invasive surgeries FDA approval creates options for patients and surgeons across a...

DGAP-News: Biom'up / Key word(s): Corporate Action Biom'up raises EUR3 million from the EUR10 million credit line granted in March 2018 by Athyrium 31.12.2018 / 18:00 The issuer is solely responsible for the content of this announcement. Biom'up raises EUR3 million from the EUR10 million credit line granted in March 2018 by Athyrium Issue of bonds with warrants attached, fully subscribed by Athyrium within the framework of the debt financing round announced on April 3, 2018. Saint-Priest,...

DGAP-News: Biom'up / Key word(s): Financing Biom'up successfully closes a EUR7.67 million private placement financing 06.12.2018 / 08:30 The issuer is solely responsible for the content of this announcement. Biom'up successfully closes a EUR7.67 million private placement financing Capital increase without preferential subscription rights to the benefit of certain categories of investors Saint-Priest, France, December 6, 2018, 8:00 (Paris time) - Biom'up (the " Company "), a specialist in...

DGAP-News: Biom'up / Key word(s): Financing Biom'up launches a private placement financing of a minimum of EUR 7 million 05.12.2018 / 19:15 The issuer is solely responsible for the content of this announcement. Biom'up launches a private placement financing of a minimum of EUR7 million Capital increase without preferential subscription rights to the benefit of certain categories of investors Delivery of the new 8,700 sqm production facility expected in 2021 Financial information update...

DGAP-News: Biom'up / Key word(s): Market Report Biom'up sees a strong commercial uptake in HEMOBLAST(TM) Bellows in the US and Europe 28.11.2018 / 08:00 The issuer is solely responsible for the content of this announcement. Biom'up sees a strong commercial uptake in HEMOBLAST TM Bellows in the US and Europe HEMOBLAST Bellows now used in 26 US hospitals and under evaluation in more than 240 hospitals, a strong sign of market adoption Acceleration of commercial roll-out in Europe with HEMOBLAST...